These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 12871354)

  • 1. Investment in prolonged thromboprophylaxis with dalteparin improves clinical outcomes after hip replacement.
    Dahl OE; Pleil AM
    J Thromb Haemost; 2003 May; 1(5):896-906. PubMed ID: 12871354
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Out of hospital antithrombotic prophylaxis after total hip replacement: low-molecular-weight heparin, warfarin, aspirin or nothing? A cost-effectiveness analysis.
    Sarasin FP; Bounameaux H
    Thromb Haemost; 2002 Apr; 87(4):586-92. PubMed ID: 12008939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extended dalteparin prophylaxis for venous thromboembolic events: cost-utility analysis in patients undergoing major orthopedic surgery.
    Dranitsaris G; Stumpo C; Smith R; Bartle W
    Am J Cardiovasc Drugs; 2009; 9(1):45-58. PubMed ID: 19178131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Economic analysis of dalteparin use in knee surgery at Instituto Mexicano del Seguro Social].
    Arreola-Ornelas H; Rosado-Buzzo A; García-Mollinedo L; Dorantes Aguilar J; Muciño-Ortega E; Mould-Quevedo JF
    Cir Cir; 2012; 80(5):411-8. PubMed ID: 23351443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-molecular-weight heparin prophylaxis using dalteparin extended out-of-hospital vs in-hospital warfarin/out-of-hospital placebo in hip arthroplasty patients: a double-blind, randomized comparison. North American Fragmin Trial Investigators.
    Hull RD; Pineo GF; Francis C; Bergqvist D; Fellenius C; Soderberg K; Holmqvist A; Mant M; Dear R; Baylis B; Mah A; Brant R
    Arch Intern Med; 2000 Jul; 160(14):2208-15. PubMed ID: 10904465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis.
    Haentjens P; De Groote K; Annemans L
    Arch Orthop Trauma Surg; 2004 Oct; 124(8):507-17. PubMed ID: 15365714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of dalteparin vs unfractionated heparin for the prevention of venous thromboembolism in critically ill patients.
    Fowler RA; Mittmann N; Geerts W; Heels-Ansdell D; Gould MK; Guyatt G; Krahn M; Finfer S; Pinto R; Chan B; Ormanidhi O; Arabi Y; Qushmaq I; Rocha MG; Dodek P; McIntyre L; Hall R; Ferguson ND; Mehta S; Marshall JC; Doig CJ; Muscedere J; Jacka MJ; Klinger JR; Vlahakis N; Orford N; Seppelt I; Skrobik YK; Sud S; Cade JF; Cooper J; Cook D; ;
    JAMA; 2014 Nov; 312(20):2135-45. PubMed ID: 25362228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin) after total hip arthroplasty--the Danish Prolonged Prophylaxis (DaPP) Study.
    Lassen MR; Borris LC; Anderson BS; Jensen HP; Skejø Bro HP; Andersen G; Petersen AO; Siem P; Hørlyck E; Jensen BV; Thomsen PB; Hansen BR; Erin-Madsen J; Møller JC; Rotwitt L; Christensen F; Nielsen JB; Jørgensen PS; Paaske B; Tørholm C; Hvidt P; Jensen NK; Nielsen AB; Appelquist E; Tjalve E
    Thromb Res; 1998 Mar; 89(6):281-7. PubMed ID: 9669750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost implications of low molecular weight heparins as prophylaxis following total hip and knee replacement.
    Bell GK; Goldhaber SZ
    Vasc Med; 2001; 6(1):23-9. PubMed ID: 11358156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enoxaparin. A pharmacoeconomic appraisal of its use in thromboembolic prophylaxis after total hip arthroplasty.
    Dunn CJ; Goa KL
    Pharmacoeconomics; 1996 Aug; 10(2):179-90. PubMed ID: 10163420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dalteparin: an update of its pharmacological properties and clinical efficacy in the prophylaxis and treatment of thromboembolic disease.
    Dunn CJ; Jarvis B
    Drugs; 2000 Jul; 60(1):203-37. PubMed ID: 10929935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic evaluation of the prophylaxis for thromboembolism in critical care trial (E-PROTECT): study protocol for a randomized controlled trial.
    Fowler RA; Mittmann N; Geerts WH; Heels-Ansdell D; Gould MK; Guyatt G; Krahn M; Finfer S; Pinto R; Chan B; Ormanidhi O; Arabi Y; Qushmaq I; Rocha MG; Dodek P; McIntyre L; Hall R; Ferguson ND; Mehta S; Marshall JC; Doig CJ; Muscedere J; Jacka MJ; Klinger JR; Vlahakis N; Orford N; Seppelt I; Skrobik YK; Sud S; Cade JF; Cooper J; Cook D; ;
    Trials; 2014 Dec; 15():502. PubMed ID: 25528663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cost-effectiveness of extended-duration antithrombotic prophylaxis after total hip arthroplasty.
    Skedgel C; Goeree R; Pleasance S; Thompson K; O'brien B; Anderson D
    J Bone Joint Surg Am; 2007 Apr; 89(4):819-28. PubMed ID: 17403806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Results of an economic model to assess the cost-effectiveness of enoxaparin, a low-molecular-weight heparin, versus warfarin for the prophylaxis of deep vein thrombosis and associated long-term complications in total hip replacement surgery in the United States.
    Botteman MF; Caprini J; Stephens JM; Nadipelli V; Bell CF; Pashos CL; Cohen AT
    Clin Ther; 2002 Nov; 24(11):1960-86; discussion 1938. PubMed ID: 12501885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prolonged thromboprophylaxis following hip replacement surgery--results of a double-blind, prospective, randomised, placebo-controlled study with dalteparin (Fragmin).
    Dahl OE; Andreassen G; Aspelin T; Müller C; Mathiesen P; Nyhus S; Abdelnoor M; Solhaug JH; Arnesen H
    Thromb Haemost; 1997 Jan; 77(1):26-31. PubMed ID: 9031444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identifying orthopedic patients at high risk for venous thromboembolism despite thromboprophylaxis.
    Schiff RL; Kahn SR; Shrier I; Strulovitch C; Hammouda W; Cohen E; Zukor D
    Chest; 2005 Nov; 128(5):3364-71. PubMed ID: 16304285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extended thromboprophylaxis following lower limb arthroplasty: what do the clinical trials mean?
    Cohen AT; Khushal A
    Haemostasis; 2000; 30 Suppl 2():88-94; discussion 82-3. PubMed ID: 11251349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subcutaneous low-molecular-weight heparin vs warfarin for prophylaxis of deep vein thrombosis after hip or knee implantation. An economic perspective.
    Hull RD; Raskob GE; Pineo GF; Feldstein W; Rosenbloom D; Gafni A; Green D; Feinglass J; Trowbridge AA; Elliott CG
    Arch Intern Med; 1997 Feb; 157(3):298-303. PubMed ID: 9040296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost effectiveness of deep venous thrombosis prophylaxis after hip fracture.
    Wade WE; Chisholm MA
    Am J Orthop (Belle Mead NJ); 2000 May; 29(5):397-9. PubMed ID: 10868442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of low molecular weight heparin (dalteparin), once daily, for the treatment of deep vein thrombosis. A feasibility and health economic study in an outpatient setting. Swedish Venous Thrombosis Dalteparin Trial Group.
    Lindmarker P; Holmström M
    J Intern Med; 1996 Dec; 240(6):395-401. PubMed ID: 9010387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.